Sanofi R&D
Our commitment to pipeline innovation
As a biopharma company committed to serving patients, Sanofi is adding to our pipeline with the aim of accelerating growth and expanding into new indications.
Our determination to find answers for patients, providers, payers, and other healthcare stakeholders motivates us to pursue medicines and vaccines with the greatest potential to improve lives and protect public health.
Sanofi R&D is expected to bring a 50% increase in the number of phase 3 studies between 2023 and 2025, creating the greatest pipeline momentum in Sanofi’s history. Our commitment to R&D will also support an estimated 25 mid- to late-stage readouts and up to 19 regulatory submissions for our pharma assets in 2024 and 2025.
![Informational callout highlighting with a strong focus on difficult-to-treat diseases and immunizations, Sanofi’s R&D pipeline includes [77] clinical-stage projects, [30] of which are in phase 3 or have been submitted to regulatory authorities for approval.](/dam/jcr:77c5bf79-9242-4d00-9c1c-f92b8f5318b9/Pipeline-callout-1-DT.svg)
Pipeline at a glance
Leadership in immunology and inflammation
Sanofi is launching multiple phase 3 clinical trials in immunology. Our scientific approach to immunology and inflammation focuses on early disease and addressing the unmet needs. The four main immunology therapeutic areas that Sanofi is targeting are gastroenterology, respiratory, dermatology, and immunologic diseases. Explore our clinical-stage immunology and inflammation pipeline below.
Targeting multiple myeloma with scientific innovation
A talented team of Sanofi scientists has their sights set on improving treatments for multiple myeloma. Our oncology pipeline currently has 6 multiple myeloma clinical trials, 4 of which are in phase 3. Scientists are evaluating the evolving endpoints used in oncology trials, such as minimal residual disease (MRD) negativity. Learn more about our oncology pipeline below.
Investing in neurology R&D
Sanofi is investigating multiple sources of damage in the brain that contribute to progression of multiple sclerosis (MS). Sanofi is also expanding the focus of our research to other neurological diseases, such as chronic inflammatory demyelinating polyneuropathy (CIDP). Get the latest on our neurology pipeline below.
Search for a specific a clinical-stage projects
Our responsible pricing commitment
See how Sanofi prioritizes accessibility and affordability through transparent pricing practices and patient support.
Diversity in clinical trials
Sanofi strives for inclusivity when designing clinical trials by partnering with historically underrepresented racial, ethnic minority, and other marginalized groups to help improve diversity in trials.
Connect with us
Schedule a meeting with a Sanofi Market Access team member to learn more about Sanofi products.
This site is intended for US payers only.
© 2024 Sanofi. All rights reserved.
